Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: LY900014 (SC)Drug: LY900014 (IV)
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT03232983
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore
A Study to Assess the Amount of LY3074828 That Gets Into the Body When Given With LY9999QS, in Healthy Participants
- Conditions
- Healthy
- Interventions
- Biological: LY3074828Biological: LY900021
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT03220126
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Leeds, United Kingdom
A Study of LY900014 in Participants With Type 1 Diabetes
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1392
- Registration Number
- NCT03214367
- Locations
- 🇺🇸
Valley Endocrine, Fresno, Fresno, California, United States
🇺🇸Physicians East, Greenville, North Carolina, United States
🇺🇸Diabetes and Endocrine Associates, La Mesa, California, United States
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: LY900014Drug: Insulin LisproDrug: Insulin GlargineDrug: Insulin DegludecDrug: MetforminDrug: SGLT2 inhibitor
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 933
- Registration Number
- NCT03214380
- Locations
- 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
🇺🇸Aventiv Research, Columbus, Ohio, United States
🇺🇸Dallas Diabetes Endocrine Center, Dallas, Texas, United States
A Study of Baricitinib in Healthy Participants
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 42
- Registration Number
- NCT03212638
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore
A Study of Two Different Formulations of LY3074828 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Biological: LY3074828
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 54
- Registration Number
- NCT03188510
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
A Study of Lasmiditan in Healthy Participants
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 35
- Registration Number
- NCT03182920
- Locations
- 🇺🇸
Covance Daytona Beach, Daytona Beach, Florida, United States
🇺🇸Covance Evansville, Evansville, Indiana, United States
A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 80
- Registration Number
- NCT03166124
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: AbemaciclibDrug: Standard Adjuvant Endocrine Therapy
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 5637
- Registration Number
- NCT03155997
- Locations
- 🇺🇸
Millennium Oncology - Hollywood, Hollywood, Florida, United States
🇺🇸Renown Regional Medical Center, Reno, Nevada, United States
🇺🇸The Valley Hospital, Inc., Paramus, New Jersey, United States
A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 566
- Registration Number
- NCT03151551
- Locations
- 🇮🇳
Sir Ganga Ram Hospital, New Delhi, Delhi, India
🇧🇪Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium
🇮🇳Krishna Institute of Medical Sciences Ltd., Secunderabad, Telengana, India